Close Menu

Caris

Investigators reported that the classifier could correctly predict cancer type with over 94 percent accuracy and highlighted impacts in a commercially tested cohort.

The company hopes the data will help convince clinicians to adopt the algorithm in CRC as it pushes forward validations for other areas like pancreatic and ovarian tumors.

News items for the in vitro diagnostic industry for the week of Oct. 19, 2020.

News items for the in vitro diagnostics industry for the week of Sept. 28, 2020.

News items for the in vitro diagnostics industry for the week of Sept. 21, 2020.

News items for the in vitro diagnostics industry for the week of August 24, 2020.

News items for in vitro diagnostics industry for the week of July 20, 2020.

Caris will sequence DNA and RNA for certain cancer patients and potentially help Merus enroll cancer patients with NRG1 fusions in the Phase I/II eNRGy trial for zenocutuzumab.

Pages